Navigation Links
Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Date:9/23/2009

RICHMOND, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania. Both Phase 1 studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic(TM) approach, however subjects' CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden will also be monitored.

"Opening a second Phase 1 clinical trial of this exciting new approach to HIV/AIDS treatment enables us to expedite clinical and commercial development of SB-728-T. We are very pleased with the FDA's decision enabling us to expand this program and move forward quickly with a repeat-dosing trial," said Dale Ando, M.D., Sangamo's chief medical officer and vice president of therapeutic development.

"The best approach to controlling HIV is by preventing infection of cells in the first place. Since 1996, when CCR5 was validated as a target for HIV therapy, the goal has been to recapitulate the naturally-occurring protection against viral infection exhibited by individuals who have the CCR5-delta32 mutation. We have the ability to disrupt the CCR5 gene and make human T-cells resistant to infection by CCR5-specific strains of HIV. In this trial we will be evaluating SB-728-T in subjects that have well-controlled levels of virus but have sub-optimal recovery of CD-4+ T-cell counts despite long-term triple drug therapy. This group represents approximately thirty per
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
2. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
3. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
7. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
8. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
9. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
10. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
11. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  Valeant Pharmaceuticals International, ... that its wholly owned subsidiary, Valeant Pharmaceuticals International, will ... amount of its 6.75% Senior Notes due 2017, CUSIP ... 15, 2014 and has mailed an irrevocable notice of ... 2014, a copy of the irrevocable notice of redemption ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne ... ambulance transport services, has been selected by Inc. ... companies in America. Photo - ... Inc. 500|5000 list identifies successful, privately-held companies with ... MedicOne Medical Response, one of only two ambulance ...
(Date:9/15/2014)...  Catalist-listed QT Vascular Ltd. ("QT Vascular" or together ... of minimally invasive medical devices for the treatment of ... has enrolled the first European patients in the ENDURE ... have already been enrolled in this study with Dr. ... Auckland, New Zealand . ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5
(Date:9/15/2014)... Florida is now one of several states ... a breath test could be forced to undergo a mandatory ... will prevent more people from drinking and driving. , ... rate of breathalyzer refusal. The new law is aimed to ... CBS Miami , the new Florida law requires people to ...
(Date:9/15/2014)... 2014 (HealthDay News) -- Births of multiple babies cost ... than singleton births, researchers report. The researchers suggest ... fertilization (IVF) could ease some of that burden. ... in tandem with births to older mothers and use ... University of New South Wales, Australia. Their study, ...
(Date:9/15/2014)... New York (PRWEB) September 15, 2014 ... Market Research "Spectrometry Market - Global Industry Analysis, Size, ... global spectrometry market was valued at USD 12,212.9 million ... million by 2020 at a CAGR of 7.2% from ... employed to access properties of light within specific electromagnetic ...
(Date:9/15/2014)... (HealthDay News) -- Adding chest radiation to chemotherapy allows ... and cuts recurrence rates by nearly 50 percent, European ... four-country study, the researchers recommended that chest radiotherapy be ... who respond to chemotherapy. , , Small-cell lung cancer ... accounts for roughly 13 percent of all lung cancers. ...
(Date:9/15/2014)... freshmen understand the benefits of eating healthy foods and know ... lack confidence in their ability to act on that knowledge, ... new University of Illinois study. , "The women in our ... healthful diet, especially if they had to do something physical ... strong if they were at a party or in places ...
Breaking Medicine News(10 mins):Health News:New DUI Law Makes Blood Tests Mandatory 2Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 2Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 4Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 5Health News:Chest Radiation May Help Fight Some Advanced Lung Cancers: Study 2Health News:Chest Radiation May Help Fight Some Advanced Lung Cancers: Study 3Health News:Freshman girls know how to eat healthy but lack confidence in their ability to do it 2
... 30 A new poll by the Pew Research ... while most Catholics who have heard about the issue ... , deep divisions exist between the most-observant Catholics and ... are divided over their assessment of Obama,s job performance.Conducted ...
... YORK, April 30 ProMetic Life Sciences Inc. ... Corporation of America ("SCOA") announces that it has ... ("SPI"), both wholly owned subsidiaries of Sumitomo Corporation ("Sumitomo") ... to PBI-1402 for the Japanese market.In the course of ...
... 2 diabetes may have unintended effects on the pancreas that could ... a greater risk of pancreatic cancer in long-term users, UCLA researchers ... published in the online edition of the journal Diabetes , ... found that sitagliptin, sold in pill form as Januvia, caused abnormalities ...
... Immucor, Inc. (Nasdaq: BLUD ), a ... blood transfusion industry, today announced that access to its ... 2009 Health Care Conference in New York, NY will ... Company,s presentation is scheduled for Tuesday, May 12, 2009, ...
... and strategic focus to neurovascular interventions developer.PALO ALTO, Calif., ... today that its directors elected Eric P. Milledge as ... industry experience, business acumen and leadership to Nfocus, ... break-through technologies in the dynamic field of endovascular neurosurgery," ...
... The Alzheimer,s Association Minnesota-North Dakota in collaboration with the ... The Alzheimer,s Project on May 12 at 6:00 p.m. ... be followed by a question-and-answer panel of medical experts ... disease, The Alzheimer,s Project shows there is now genuine ...
Cached Medicine News:Health News:New Poll on Obama, Catholics and the Notre Dame Commencement Finds Deep Divisions Among Catholics 2Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 2Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 3Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 4Health News:Popular diabetes treatment could trigger pancreatitis, pancreatic cancer 2Health News:Popular diabetes treatment could trigger pancreatitis, pancreatic cancer 3Health News:Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board 2Health News:The Alzheimer's Project HBO Documentary Puts Spotlight On Alzheimer's Disease; Premiere Screening at the Hennepin County Library in Downtown Minneapolis 2
... is lightweight enough to shuttle easily between ... Designed with a goldmann standard 30 cm ... with 79 locations (including 30-2, 24-2, and ... different suprathresholds out to 30. Easyfield ...
... detections of any possible ... glaucoma in the visual ... Smooth operation of kinetic ... accuracy of static and ...
Focus Toric Monthly lenses. All the advantages of Focus Monthly lenses, now available for patients with astigmatism. Recommended for daily wear. Also approved for extended wear (1-7 days)....
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
Medicine Products: